EGFR and non-small cell lung carcinoma: Futhermore, the introduction of anti-PD-1/PD-L1 therapy and EGFR-TKIs for heavily pretreated patients with NSCLC had also created a dilemma regarding whether anti-PD-1/PD-L1 agent was better than EGFR-TKIs, or vice versa.